Hydrocortisone Plus Fludrocortisone in High-risk Patients Undergoing for Cardiac Surgery
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 196
- 试验地点
- 2
- 主要终点
- Variation of acute kidney injury occurence between both groups
研究概览
简要总结
Cardiac surgery is a high-risk surgery and is associated with a rate of postoperative adverse outcomes. Like many others major surgery, cardiac surgery procedures induce a proinflammatory phase usually counterbalanced with an immunosuppressive phase so the immune response remained balanced.
In some cases, the immune response might be dysregulated with a more pronounced pro inflammatory state that compromises organ perfusion and with the occurrence of organ failure. From a mechanistic approach, the relationship between organ failure is complex and multifactorial with a high level of proinflammatory cytokines, a decrease in microcirculation, an endothelial dysfunction and an activation of coagulation and over. The clinical expression is an increase in vasopressor exposure and dose, an increase in mortality and in adverse outcomes with a predominance of acute kidney injury.
Various therapies have been assessed to manage cardiac surgery related sepsis including glucocorticoid therapy. Briefly, two major randomized trials assessed glucocorticoid therapy solely in scheduled cardiac surgery with cardiopulmonary bypass. No clinical benefit was demonstrated in term of reduction in postoperative mortality or adverse outcomes. Since, data support that the selection of patients at risk is crucial to demonstrate such a strategy. Indeed, data support that surprisingly some patients will have a very light immune response reflected by a low pro inflammatory cytokine.
The hypothesis is that the combination glucocorticoid and fludrocortisone could decrease adverse outcomes in selected patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years.
- •Patient at intermediate/high risk (EuroSCORE II > 4%).
- •Patient admitted for scheduled cardiac surgery:
- •Coronary artery bypass grafting (CABG).
- •Aortic valve replacement.
- •Mitral valve repair or replacement.
- •Surgery of the aortic root (aortic tube, Bentall procedure, Tirone David procedure, or other).
- •Combined surgery.
- •Patient undergoing cardiopulmonary bypass (CPB).
- •Informed consent signed by the patient.
排除标准
- •Endocarditis
- •Off-pump heart surgery
- •Heart transplantation or long-term ventricular assist device (VAD)
- •Emergency surgery: aortic dissection, emergency coronary artery bypass grafting (CABG)
- •Failure to wean from CPB requiring short-term mechanical support (intra-aortic balloon pump, ECMO)
- •Hypothermic surgery
- •History of cardiac surgery
- •Patient on long-term corticosteroid therapy
- •Autoimmune disease or chronic inflammatory condition
- •End-stage renal disease on long-term dialysis
- •Contraindications to the administration of hydrocortisone and/or fludrocortisone according to the summary of product characteristics (SmPC)
- •Pregnant or breastfeeding woman
- •Patient under legal protection (guardianship, curators, or judicial safeguard).
研究组 & 干预措施
hydrocortisone plus fludrocortisone
- Hydrocortisone 200 mg/day for 5 days or until ICU discharge, starting at the initiation of cardiopulmonary bypass (CPB), administered intravenously via syringe pump in a double-blind manner
- Fludrocortisone 50 µg/day in the morning for 5 days or until ICU discharge, administered orally or via nasogastric tube (if the patient is sedated), diluted in a glass of water, in a double-blind manner
干预措施: hydrocortisone plus fludrocortisone (Drug)
placebo of hydrocortisone plus fludrocortisone
- Placebo for hydrocortisone (0.9% NaCl) administered following the same protocol as fludrocortisone in the intervention group
- Placebo for fludrocortisone (capsule containing microcrystalline cellulose diluted in a glass of water) administered following the same protocol as fludrocortisone in the intervention group
干预措施: placebo of hydrocortisone plus fludrocortisone (Drug)
结局指标
主要结局
Variation of acute kidney injury occurence between both groups
时间窗: up to 7 days
Variation of postoperative pulmonary complication occurrence between both groups
时间窗: up to 7 days
Variation of number of norepinephrine requirement between both groups
时间窗: up to 7 days
次要结局
- variation of postoperative atrial fibrillation occurence between both groups(up to 7 days)
- variation of myocardial infarction occurence between both groups(up to 7 days)
- variation of stroke occurence between both groups(up to 7 days)
- Variation of total amount of norepinephrine between both groups(up to 7 days)
- variation of occurrence of glucocorticoid side effect between both groups(up to 7 days)
- Variation of 28-day mortality between both groups(at 28 days)